In GBM patients, the IAP protein, survivin, was demonstrated to be mainly expressed in patient-derived GBM stem cells compared to differentiated cells, with a predominant localization in the core of tumor mass and associated with the expression of CD133, SOX2 and MELK (48). The gene discussed is SOX2; the disease is glioblastoma.